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EDITORIAL COMMENTARYMyocardial protection isn’t dead yetDonald D. Glower, MDSee related article on pages 2296-308.Myocardial protection has been at the cutting edge cardiac
surgical research for much of the last 50 years, yet today it is
taken for granted. Many hospital pharmacies compound
their own local cardioplegic solutions with good results,
suggesting that little mystery remains to myocardial protec-
tion. Lest we be too smug, however, Chen-Scarabelli and
colleagues provide insight into yet another potential mech-
anism by which patients with diabetes may be more suscep-
tible to cardiac injury during cardiac arrest. Chen-Scarabelli
and colleagues nicely show that, among human subjects
undergoing cardiac surgery, relative to control subjects
without diabetes those with diabetes have lower baseline
myocardial levels of urocortin and do not demonstrate over-
expression of cardiac urocortin after cardioplegic arrest.
Urocortin is a 40–amino acid peptide that is known to
be involved in regulating feeding activity in animals
stressed by fasting. Urocortin has vasodilatory properties,
and it is known to have cardioprotective properties during
myocardial ischemia. The mechanisms that cause urocor-
tin to be present at lower baseline levels and fail to over-
express during ischemia in the diabetic heart are unclear.
Future research could certainly target these mechanisms
for pharmacologic manipulation with cardioplegic addi-
tives, or one might find means to better prepare patientsFrom the Department of Surgery, Duke University Medical Center, Durham, NC.
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The Journal of Thoracic and Carwith diabetes for cardiac surgery by means of preopera-
tive therapies.
The study by Chen-Scarabelli and colleagues is a good
example of early translation research, taking known basic
science phenomena and examining them in real clinical
patients undergoing cardiac surgery. Chen-Scarabelli and
colleagues have made good use of myocardial biopsy in
the operating room before and after cardioplegic arrest to
provide small amounts of myocardium for biochemical or
structural analysis. Intraoperative myocardial biopsy has
been able to detect ischemia-induced myocardial changes
at their worst, within minutes to a few hours after release
of the crossclamp. Translating observed changes in urocor-
tin seen on myocardial biopsy into practical changes in
myocardial protection will require further investigation.
In the big picture today, heart failure remains a big part of
perioperative mortality and morbidity in cardiac surgery. In
most patients, perioperative heart failure can be attributed to
impaired preoperative cardiac function. Evenmild and tran-
sient cardiac injury in the operating room as a result of poor
myocardial protection can significantly influence outcome,
however, particularly in those increasingly common pa-
tients with baseline cardiac dysfunction.
Until cardiac replacement therapy becomes more avail-
able and more benign, we will need much more work like
that of Chen-Scarabelli and colleagues to help us get
patients with abnormal and injured hearts safely through
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